ATAI News and Press, ATAI Life Sciences N.V. From 03/31/23

2023-03-31 09:53:39 ET Atai Life Sciences (NASDAQ: ATAI) , a small-cap drugmaker developing psychedelic-based treatments for drug dependency and mental health disorders, posted strong gains during the first four days of trading this week. Specifically, the biotech's stock gained...

The past few years have seen the emergence of a relatively new and controversial mode of treatment in the psychiatric sector: psychedelic-assisted therapies . As more scientists across the country have turned their attention to psychedelics and its possible benefits, a growing body of research h...

2023-03-29 10:05:07 ET Gainers: Kodiak Sciences ( KOD ) +19% . Arcturus Therapeutics ( ARCT ) +16% . Erasca ( ERAS ) +15% . G Medical Innovations ( GMVD ) +15% . Atai Life Sciences ( ATAI ) +13% . Losers: ProQR The...

2023-03-24 07:23:35 ET ATAI Life Sciences press release ( NASDAQ: ATAI ): Q4 GAAP EPS of -$0.28 misses by $0.05 . Revenue of $0.04M (-82.6% Y/Y) misses by $0.07M . Cash and cash equivalents and short-term investments were $273.1 million as of December 31, 2022,...

atai’s development candidates, such as RL-007 and GRX-917, all represent significant opportunities to address unmet medical needs of patients living with mental health conditions Continued operational progress on robust clinical pipeline, with multiple phase 1 and phase 2 proof-of-...

A growing body of scientific literature has revealed that psychedelics have the potential to treat a variety of mental disorders. Drugs such as ketamine, ecstasy (MDMA) and psilocybin have shown in clinical studies that they are capable of treating psychiatric disorders , including treatment-res...

Psychedelics have been enjoying increased media attention in recent years due to their therapeutic potential. Research and clinical studies on the applications of hallucinogenic drugs has revealed that they are capable of treating the symptoms of mental health conditions such as major depressi...

2023-03-06 12:27:13 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The psychedelic drug boom may be taking off, but one company in the space is trimming its workforce. Atai Life Sciences (NASDAQ: ATAI ) just announced it has laid off roughl...

2023-03-06 07:44:23 ET Atai Life Sciences ( NASDAQ: ATAI ) has reduced its workforce by ~30% as part of a strategic review, the company said while providing other clinical and corporate updates. Atai noted that the decision to reduce workforce was taken after a strategi...

RL-007: First patient dosed in the on-going phase 2b study in cognitive impairment associated with schizophrenia GRX-917: Intention to progress GRX-917 into a phase 2 study in an anxiety disorder as the next step in clinical development COMP360: Recently announced acceleration o...